Command Palette

Search for a command to run...

AMBUJACEM

547.55-8.2 (-1.48%)

Quarterly ResultsProfit & LossBalance SheetCash Flow

Key Insights

POSITIVE
  • Net Sales increased significantly to ₹9888.61 crore in Q1 2025, showing strong demand recovery.
  • Operating profit improved to ₹1066.91 crore, indicating better cost management and efficiency.
  • Net profit surged to ₹1282.24 crore, reflecting enhanced profitability compared to earlier quarters.
NEGATIVE
  • Company experienced a cash flow shortfall with a 10% decrease this year [Dummy Data]
  • Company’s strategic partnerships have yet to generate expected growth. [Dummy Data]
  • Company’s EBITDA shrank at a CAGR of -8% over the past 3 years. [Dummy Data]
Quarterly Results Data
FieldTrendDec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25
Revenue
8,128.808,893.998,311.487,516.119,328.569,888.6110,289.109,174.49
Expenses
6,884.547,741.317,566.917,023.498,347.688,821.709,256.698,375.59
Operating Profit
1,244.261,152.68744.57492.62980.881,066.911,032.41798.90
Other Income
193.65233.46354.72374.031,352.24573.26256.09257.04
Interest
70.1492.9167.8166.8566.9914.2967.1476.82
Depreciation
417.70453.06467.43551.96663.98786.35861.57885.15
Profit Before Tax
1,448.121,601.141,102.68712.672,336.071,779.561,332.63837.53
Tax
358.5775.36313.05239.78-284.02497.32362.97-1,464.75
Net Profit
1,089.551,525.78789.63472.892,620.091,282.24969.662,302.28
EPS in Rs
4.145.312.671.858.593.883.207.15